Wednesday, May 20, 2026
← Back to archivePolicy
Policy•Fierce Pharma•May 20, 2026
Takeda slapped with $885M verdict in pay-for-delay antitrust case
background ▾
- •Takeda faces up to $2.655 billion in total damages if treble damages are applied under antitrust law, with the company planning an appeal
- •This is a landmark pay-for-delay verdict that could signal stronger FTC/DOJ enforcement and increase litigation risk for other branded manufacturers with similar settlement practices
- •Monitor Takeda's appeal strategy and any precedent-setting outcomes that may reshape branded-generic settlement negotiations industry-wide
Takeda
→ Read original articlePolicy•STAT News•May 20, 2026
NIH behind in filling top roles, with 15 of 27 institutes led by acting directors
background ▾
- •55% of NIH institutes lack permanent leadership, hampering long-term research planning and destabilizing the research community at a time of unprecedented federal funding priority shifts
- •The Trump administration has broken historical precedent by non-renewing director contracts and circumventing traditional external search committees, with evidence of political influence in at least one high-profile appointment (NIEHS director Kyle Walsh)
- •Congressional action via Senate Appropriations Committee indicates this has become a governance crisis; watch for legislative mandates on search procedures and potential confirmation battles for permanent directors
Policy•STAT News•May 20, 2026
Opinion: The rise of perimenopause misinformation
background ▾
- •Academic researchers from Georgetown's Pharmed Out project are challenging the expanding attribution of multiple symptoms to perimenopause and questioning commercial incentives driving symptom expansion
Policy•STAT News•May 19, 2026
Trump’s cuts to foreign aid are undermining the Ebola response, insiders say
background ▾
- •U.S. foreign aid to DRC was slashed by ~70% (from $33M to <$10M annually), directly eliminating or freezing Ebola-focused surveillance, detection, and response programs during the lead-up to the current outbreak
- •Multiple public health workers report the funding cuts materially degraded epidemic preparedness infrastructure—including protective equipment, surveillance systems, and front-line response capacity—that likely affected outbreak detection speed and containment effectiveness
- •Monitor whether this outbreak becomes a focal point for Congressional scrutiny of foreign aid cuts and whether it influences policy debate around U.S. infectious disease prevention funding and WHO engagement
International Rescue CommitteeWorld Health Organization
→ Read original articlePolicy•KFF•May 19, 2026
State Health Coverage for Immigrants and Implications for Health Coverage and Care
background ▾
- •The 2025 reconciliation law restricts federal coverage (Medicaid, CHIP, ACA subsidies, Medicare) for lawfully present immigrants to only LPRs, green card holders, and select other designated groups—a major policy shift affecting eligibility thresholds and waiting periods.
- •States are diverging in response: some are expanding state-funded programs to fill federal gaps, while others are reducing existing programs due to budget constraints, creating a fragmented landscape of coverage across the country.
- •Monitor state legislative action over the next 12-24 months as states balance budget pressures against growing coverage gaps; outcomes will shape uninsured rates, healthcare utilization patterns, and demand for charity care and safety-net programs that could indirectly affect pharma market access and patient populations.
Market Access
Market Access•Fierce Pharma•May 20, 2026
Roche signs generic Xofluza licensing deal with Medicines Patent Pool for 129 countries
background ▾
- •Roche voluntarily licensed Xofluza to the Medicines Patent Pool, enabling generic production in 129 developing countries—a significant access expansion for an important seasonal and pandemic influenza therapeutic.
- •This market-segmentation strategy preserves Roche's commercial position in wealthy markets while building goodwill and addressing WHO/public health pressure for equitable access to antivirals.
- •Watch for: actual generic manufacturer uptake, competitive generic pricing, impact on Roche's influenza franchise revenues, and whether similar agreements extend to other antivirals in pandemic preparedness.
RocheMedicines Patent PoolXofluzabaloxavir marboxil
→ Read original articleMarket Access•Fierce Biotech•May 19, 2026
Facing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up
background ▾
- •Upfront payments for Chinese biotech licensing deals have surged 230% since 2022 (from $52M to $172M), with the largest reaching $1.25B, driven by clinical validation of the PD-1/VEGF bispecific class.
- •Chinese companies now represent 50% of global out-licensing deal volume versus 28% for U.S. and <20% for Europe, fundamentally reshaping pharma's R&D sourcing strategy.
- •Larger pharmas are establishing on-the-ground presence in China and employing specialized advisors to access undisclosed deal flow, as traditional sourcing methods prove insufficient in a rapidly consolidating market.
Merck & Co.AbbVieLaNova MedicinesKeytrudaivonescimab
→ Read original articleMarket Access•Endpoints News•May 19, 2026
Another Paragon offshoot chooses reverse merger, this time for migraine drugs
background ▾
- •Paragon Therapeutics is executing another reverse merger as part of its recurring corporate strategy
Paragon Therapeutics
→ Read original articleMarket Access•Fierce Biotech•May 20, 2026
Parabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug’s phase 3 push
background ▾
- •Parabilis secured $125M upfront and equity commitment from Regeneron—major validation of helicon peptide platform that enables targeting of previously undruggable flat protein surfaces
- •Zolucatetide targets beta-catenin, a decades-long Holy Grail in drug discovery; FDA fast-track designation in November 2025 de-risks phase 3 pathway for desmoid tumors
- •IPO comes amid reopened biotech capital markets (Kailera's $625M obesity drug IPO last month); watch for zolucatetide phase 3 initiation timing and helicon platform adoption by Regeneron
Parabilis MedicinesRegeneron PharmaceuticalsJohnson & Johnsonzolucatetide
→ Read original articleMarket Access•Endpoints News•May 19, 2026
TrumpRx adds hundreds of generic medicines to site
background ▾
- •TrumpRx platform now offers 600+ generic medicines, substantially expanding its therapeutic reach and potential patient accessibility
- •This represents a policy-driven market access initiative aimed at bypassing traditional pharmacy and insurance intermediaries
- •Implications for generic drug pricing, traditional pharmacy networks, and payer reimbursement models require further clarification as the platform scales
Clinical Trials
Clinical Trials•Fierce Biotech•May 19, 2026
Merck inks Keytruda supply pact to support Exelixis’ colorectal cancer trial
background ▾
- •Merck will supply Keytruda Qlex for Exelixis' phase 3 MRD-positive colorectal cancer trial, enabling the company to test zanzalintinib in combination with checkpoint inhibition in the adjuvant setting
- •This represents a competitive repositioning: Exelixis pivots from Tecentriq (partnering with Roche in metastatic disease) to Keytruda for the MRD-adjuvant indication, expanding Merck's oncology portfolio reach
- •Watch for trial initiation in mid-2026 and competitive dynamics with Taiho's Lonsurf, which showed 9.3-month median DFS in similar patients; also monitor Exelixis' Dec. 3 FDA decision on zanzalintinib-Tecentriq in metastatic colorectal cancer
ExelixisMerck & Co.NateraKeytruda QlexzanzalintinibTecentriq
→ Read original articleClinical Trials•Fierce Biotech•May 19, 2026
Relay ‘full steam ahead’ on PI3K inhibitor fueled by first phase 2 data in blood vessel disorder
background ▾
- •60% volumetric response rate at Week 12 in evaluable patients represents the first demonstration of selective PI3Kα inhibition efficacy in vascular anomalies, addressing a historically difficult-to-treat rare disease with no approved systemic therapies
- •Relay's selective PI3Kα inhibitor approach appears to overcome historical toxicity limitations (hyperglycemia, skin integrity issues) that have plagued broader PI3K inhibitors like Novartis' Piqray, enabling chronic dosing in this patient population
- •Watch for Phase 2 completion and regulatory path forward; competitive landscape includes Roche's Itovebi and Eli Lilly's PI3K program (via Scorpion Therapeutics acquisition), so differentiation on safety and efficacy in VA will be critical for market positioning
Relay TherapeuticsNovartisAstraZenecazovegalisibPiqrayFaslodex
→ Read original articleClinical Trials•Fierce Pharma•May 20, 2026
UCB digs deeper into Bimzelx’s psoriatic arthritis win over Skyrizi
background ▾
- •Bimzelx demonstrated statistically significant superiority over Skyrizi in reducing disease activity (49% vs 38% at Week 16) in phase 3b psoriatic arthritis trial
- •This is the first published head-to-head efficacy comparison between these two IL-17 inhibitors in psoriatic arthritis, providing direct clinical evidence for competitive differentiation
- •Watch for impact on treatment guidelines, formulary positioning, and physician prescribing patterns in psoriatic arthritis; monitor for any comparable head-to-head data from other IL-17 inhibitors
UCBAbbVieBimzelxSkyrizi
→ Read original articleClinical Trials•Fierce Biotech•May 20, 2026
Pfizer furthers pneumococcal efforts, remains ‘comfortable’ taking on emerging threats: vaccine chief
background ▾
- •25vPnC demonstrated immunological superiority over Prevnar 20, particularly for serotype 3, which causes 15-20% of pneumococcal infections with mortality rates as high as 47%
- •Pfizer is bifurcating its development strategy: pursuing 25vPnC rapidly in infants while advancing a 35-variant candidate for adults, reflecting realistic timeline constraints in pediatric vaccine development
- •Watch for phase 3 infant trial results (initiated this month), adult efficacy data for serotype 3 approaches, and regulatory decisions on whether 25vPnC or 35vPnC becomes the preferred next-generation standard
PfizerPF-0787241225vPnCPrevnar 20
→ Read original articleClinical Trials•STAT News•May 19, 2026
How AI helped treat a newborn’s ultra rare disease. ‘It was almost like a light switch.’
background ▾
- •AI-driven drug repurposing identified clonazepam as effective treatment for ultra-rare genetic disorder, enabling dramatic clinical recovery in a previously severely disabled newborn
- •The Biomedical Data Translator, an NIH-funded open-source knowledge graph, proved essential in making biomedical connections across literature that clinicians could not identify manually
- •Scaling barriers include widespread unavailability of genomic sequencing and difficulty implementing rapid laboratory testing across diverse health systems—watch for NIH funding initiatives and health system partnerships to address infrastructure gaps
Mayo ClinicclonazepamKlonopin
→ Read original article